Eli Lilly and Company

Named Patient Use Program to Provide Abemaciclib (LY2835219) for the Treatment of Metastatic Breast Cancer

Official Title: 
Named Patient Use Program to Provide Abemaciclib for the Treatment of Metastatic Breast Cancer
Brief Summary: 
The treating physician/investigator contacts Lilly when, based on their medical opinion, a patient meets the criteria for inclusion in the expanded access program.
Available
EA Type
Individual Patients
Metastatic Breast Cancer

Drug: Abemaciclib
Administered orally.
Other Name: LY2835219

Eligibility Criteria: 

Inclusion Criteria:

- Patients with hormone receptor positive metastatic breast cancer for whom there is reasonable expectation that abemaciclib may provide clinical benefit and who are suitable to receive abemaciclib.

Eligibility Gender: 
All
Eligibility Age: 
Minimum: 18 Years
Countries: 
Australia, Canada, Egypt, Italy, Korea, Republic of, Malaysia, Singapore, South Africa, Spain, Switzerland, Taiwan, United Kingdom
Contacts: 

There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or
1-317-615-4559
clinicaltrials.gov@lilly.com

Eli Lilly and Company
EA Number: 
MeSH Terms: 
Breast Neoplasms
Disclaimer:
Expanded Access program information for companies listed in the Expanded Access Company Directory is pulled daily from ClinicalTrials.gov, a resource provided by the National Institutes of Health in cooperation with the U.S. Food and Drug Administration. Click here for more information about ClinicalTrials.gov.